Last reviewed · How we verify
Group C:TDF and Peginterferon alfa-2a then TDF
Group C:TDF and Peginterferon alfa-2a then TDF, marketed by Ruijin Hospital, holds a position in the treatment landscape for its primary indication, though specific revenue figures are not disclosed. The key strength of this regimen lies in its unique combination therapy approach, which may offer improved efficacy over monotherapy options. A primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Group C:TDF and Peginterferon alfa-2a then TDF |
|---|---|
| Also known as | tenofovir,pegasys |
| Sponsor | Ruijin Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: